GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » New Horizon Health Ltd (HKSE:06606) » Definitions » Cash Flow from Financing

New Horizon Health (HKSE:06606) Cash Flow from Financing : HK$1,027 Mil (TTM As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is New Horizon Health Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Jun. 2023, New Horizon Health received HK$733 Mil more from issuing new shares than it paid to buy back shares. It received HK$219 Mil from issuing more debt. It paid HK$0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received HK$0 Mil from paying cash dividends to shareholders. It spent HK$8 Mil on other financial activities. In all, New Horizon Health earned HK$944 Mil on financial activities for the six months ended in Jun. 2023.


New Horizon Health Cash Flow from Financing Historical Data

The historical data trend for New Horizon Health's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

New Horizon Health Cash Flow from Financing Chart

New Horizon Health Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Cash Flow from Financing
-7.05 418.19 512.62 2,184.23 84.29

New Horizon Health Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only 2,187.15 -32.65 -12.17 95.88 930.62

New Horizon Health Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

New Horizon Health's Cash from Financing for the fiscal year that ended in Dec. 2022 is calculated as:

New Horizon Health's Cash from Financing for the quarter that ended in Jun. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$1,027 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


New Horizon Health  (HKSE:06606) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

New Horizon Health's issuance of stock for the six months ended in Jun. 2023 was HK$733 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

New Horizon Health's repurchase of stock for the six months ended in Jun. 2023 was HK$0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

New Horizon Health's net issuance of debt for the six months ended in Jun. 2023 was HK$219 Mil. New Horizon Health received HK$219 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

New Horizon Health's net issuance of preferred for the six months ended in Jun. 2023 was HK$0 Mil. New Horizon Health paid HK$0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

New Horizon Health's cash flow for dividends for the six months ended in Jun. 2023 was HK$0 Mil. New Horizon Health received HK$0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

New Horizon Health's other financing for the six months ended in Jun. 2023 was HK$-8 Mil. New Horizon Health spent HK$8 Mil on other financial activities.


New Horizon Health Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of New Horizon Health's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


New Horizon Health Business Description

Traded in Other Exchanges
N/A
Address
400 Jiang’er Road, 13th Floor, T1 Building, Binjiang District, Zhejiang, Hangzhou, CHN, 310052
New Horizon Health Ltd is engaged in early cancer screening and in-home testing in China. The company has an early detection and cancer screening-focused pipeline of five products and product candidates with an emphasis on colorectal cancer screening. The company focuses on cancer prevention and cure through screening and early detection. It generates maximum revenue from ColoClear and Pupu Tube products.
Executives
Invesco Advisers, Inc. 2102 Investment manager
Chen Yiyou 2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited 2301 Trustee
Bancasa Holding Limited 2201 Interest of corporation controlled by you
Mst Development Limited 2101 Beneficial owner
Yao Naxin 2305 Beneficiary of a trust
Janus Henderson Group Plc 2102 Investment manager
Jpmorgan Chase & Co. 2106 Person having a security interest in shares
Invesco Developing Markets Fund 2106 Person having a security interest in shares
Zhu Yeqing 2101 Beneficial owner
Qiming Venture Partners V, L.p.
Qiming Gp V, L.p.
Qiming Corporate Gp V, Ltd.
Bei Jing Jun Qi Jia Rui Qi Ye Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Jun Lian Zi Ben Guan Li Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you

New Horizon Health Headlines

No Headlines